Nantong Jinghua Pharmaceutical Co Ltd - Asset Resilience Ratio
Nantong Jinghua Pharmaceutical Co Ltd (002349) has an Asset Resilience Ratio of 8.36% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Nantong Jinghua Pharmaceutical Co Ltd (002349) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Nantong Jinghua Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002349 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Nantong Jinghua Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 002349 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥302.35 Million | 8.36% |
| Total Liquid Assets | CN¥302.35 Million | 8.36% |
Asset Resilience Insights
- Limited Liquidity: Nantong Jinghua Pharmaceutical Co Ltd maintains only 8.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nantong Jinghua Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nantong Jinghua Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Nantong Jinghua Pharmaceutical Co Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Nantong Jinghua Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.18% | CN¥434.74 Million ≈ $63.62 Million |
CN¥3.57 Billion ≈ $522.45 Million |
+8.99pp |
| 2024-12-31 | 3.18% | CN¥105.16 Million ≈ $15.39 Million |
CN¥3.30 Billion ≈ $483.15 Million |
-6.79pp |
| 2023-12-31 | 9.97% | CN¥317.69 Million ≈ $46.49 Million |
CN¥3.19 Billion ≈ $466.07 Million |
+5.87pp |
| 2022-12-31 | 4.11% | CN¥124.95 Million ≈ $18.28 Million |
CN¥3.04 Billion ≈ $445.09 Million |
-2.56pp |
| 2021-12-31 | 6.67% | CN¥213.36 Million ≈ $31.22 Million |
CN¥3.20 Billion ≈ $467.98 Million |
+3.04pp |
| 2020-12-31 | 3.64% | CN¥114.74 Million ≈ $16.79 Million |
CN¥3.16 Billion ≈ $461.83 Million |
+2.40pp |
| 2019-12-31 | 1.23% | CN¥36.27 Million ≈ $5.31 Million |
CN¥2.94 Billion ≈ $430.41 Million |
+0.36pp |
| 2018-12-31 | 0.87% | CN¥29.64 Million ≈ $4.34 Million |
CN¥3.40 Billion ≈ $497.48 Million |
-- |
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. It also pr… Read more